A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Background: Frail and elderly patients ...
A TURBT allows examination beyond the bladder. Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for ...
A phase II clinical trial of intravesical YH01 for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC). RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan for ...
Bladder cancer is the seventh most common cancer in men, with nearly 400,000 cases diagnosed per year. However, despite the use of transurethral resection of the bladder tumor (TURBT), a large number ...
In a trial of low-grade Ta bladder cancer, photocoagulation was noninferior to standard TURBT in maintaining recurrence-free survival. Office-based laser photocoagulation provides 12-month ...
Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses. Patients with recurrent low-grade intermediate-risk ...
Obtaining detrusor muscle during TURBT is important for assessing the stage and type of bladder cancer, which can help to identify the most effective treatment. The following measures can be used to ...
About - It is an endoscopic procedure performed to remove the bladder lesion for further analysis of its nature by histopathology. Procedure - Usually performed under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results